Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09AX Other drugs for disorders of the musculo-skeletal system
M09AX07 Nusinersen
D10791 Nusinersen sodium (JAN) <JP/US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Nusinersen
D10791 Nusinersen sodium (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D10791 Nusinersen sodium (JAN)
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Signaling molecules
Spliceosome
SMN2
D10791 Nusinersen sodium (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10791
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10791
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10791
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10791
